Un estudio para evaluar los patrones de tratamiento y la adherencia al tratamiento en participantes con cáncer de mama HER2-positivo temprano después de la descentralización del tratamiento (Close2HER)
Investigación en el Mundo Real de los Patrones de Tratamiento y la Adherencia al Tratamiento en el Cáncer de Mama HER2-positivo Temprano en Serbia tras la Descentralización del Tratamiento (Close2HER)
The main purpose of this study is to evaluate the impact of a decentralized treatment model on treatment adherence in participants with early-stage human epidermal growth factor receptor 2- positive (HER2+) breast cancer (BC).
This study has 2 groups: Group 1: Consistent Travel Burden (Cohorts A, C, and D), will include participants whose adjuvant therapy location does not increase their travel requirements, and Group 2: Increased Travel Burden (Cohort B), will include participants who must travel from a secondary center to a tertiary center to receive their adjuvant therapy.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Copia de seguridad de contactos de estudio
- Nombre: Reference Study ID Number: ML46477 https://forpatients.roche.com/ No attachments to email below.
- Número de teléfono: 888-662-6728 (U.S. Only)
- Correo electrónico: global-roche-genentech-trials@gene.com
Ubicaciones de estudio
-
-
Bolnička 65
-
Loznica, Bolnička 65, Serbia, 15300
- Reclutamiento
- Health Centre Loznica
-
-
Bratstva Jedinstva 135
-
Požarevac, Bratstva Jedinstva 135, Serbia, 12000
- Reclutamiento
- General Hospital Požarevac
-
-
Dragiše Mišovića 1
-
Bor, Dragiše Mišovića 1, Serbia, 19210
- Reclutamiento
- Healthcare Centre Bor
-
-
Dunavska 1-3
-
Kladovo, Dunavska 1-3, Serbia, 19320
- Reclutamiento
- Health Centre Kladovo
-
-
Knez Mihailova 51
-
Smederevo, Knez Mihailova 51, Serbia, 11300
- Reclutamiento
- Health Centre ''Sveti Luka'' Smederevo
-
-
Miloša Trebinjca 11
-
Pančevo, Miloša Trebinjca 11, Serbia, 26000
- Reclutamiento
- General Hospital Pančevo
-
-
Pasterova 14
-
Belgrade, Pasterova 14, Serbia, 11000
- Reclutamiento
- Institute for Onocology and Radiology of Serbia
-
-
Popa Karana 2-4
-
Šabac, Popa Karana 2-4, Serbia, 15000
- Reclutamiento
- General Hospital "Dr Laza K. Lazarevic" Sabac
-
-
Sinđelićeva 62
-
Valjevo, Sinđelićeva 62, Serbia, 14000
- Reclutamiento
- Health Centre Valjevo
-
-
Vuka Karadžića 147
-
Smederevska Palanka, Vuka Karadžića 147, Serbia, 11420
- Reclutamiento
- General Hospital ''Stefan Visoki'' Smederevska Palanka
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
The study population will consist of participants diagnosed with HER2-positive eBC who are initiating or undergoing treatment following a nationwide healthcare policy change in Serbia that decentralized the administration of anti-HER2 therapies.
Descripción
Inclusion Criteria:
- Diagnosis of stage II and III HER2+ eBC according to European Society For Medical Oncology (ESMO) guidelines
- Underwent curative-intent surgical resection for BC
- Histologically documented HER2-positive BC (determined per American Society of Clinical Oncology [ASCO]/College of American Pathologists [CAP] guidelines) before or after surgery
Exclusion Criteria:
- Any medical or psychiatric condition that, in the investigator's opinion, would compromise the participant's ability to provide informed consent or to complete study-related questionnaires
- Receipt of prior neoadjuvant or adjuvant therapy for HER2+ BC at a center other than the 10 participating study sites (Bor, Kladovo, Institute for oncology and Radiology of Serbia (IORS), Loznica, Pančevo, Požarevac, Smederevo, Smederevska Palanka, Šabac, Valjevo)
- Participants administratively belonging to the following secondary centers: Bor, Kladovo, Loznica, Pančevo, Požarevac, Smederevo, Smederevska Palanka, Šabac, or Valjevo, who initiated neoadjuvant therapy at IORS instead of their local secondary center
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
|---|
|
Group 1: Cohort A
Participants who received neoadjuvant therapy and achieved pathological complete response (pCR) and receive their adjuvant treatment at a designated secondary or tertiary center, administratively assigned based on their place of residence will be observed to assess the impact on quality of life (QoL) and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
|
Group 2: Cohort B
Participants who received neoadjuvant therapy at a secondary center and were subsequently found to have residual invasive disease will be referred to a centralized referent tertiary institution to receive their adjuvant treatment and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
|
Group 1: Cohort C
Participants who received neoadjuvant therapy at their designated tertiary center, which is the institution administratively assigned based on their place of residence, and subsequently found to have residual invasive disease will continue with adjuvant treatment at the same institution, and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
|
Group 1: Cohort D
Participants who missed neoadjuvant therapy and underwent primary BC surgery will start adjuvant treatment at their designated secondary hospital or tertiary center, which is the institution administratively assigned based on their place of residence and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Tasa de Adherencia al Tratamiento
Periodo de tiempo: Hasta 2.25 años
|
Hasta 2.25 años
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Tasa de Finalización del Tratamiento para el Tratamiento Anti-HER2
Periodo de tiempo: Hasta 2,25 años
|
Hasta 2,25 años
|
|
|
Porcentaje de participantes con ≥1 retrasos en la dosis que superan un umbral predefinido (3 semanas) desde la fecha programada
Periodo de tiempo: Hasta 2.25 años
|
Hasta 2.25 años
|
|
|
Tiempo hasta el inicio del tratamiento adyuvante
Periodo de tiempo: Tiempo desde la cirugía hasta el inicio del tratamiento adyuvante (hasta aproximadamente 1,25 años)
|
Tiempo desde la cirugía hasta el inicio del tratamiento adyuvante (hasta aproximadamente 1,25 años)
|
|
|
Mean Travel Burden Between Group 1 (Cohorts A, C, D) and Group 2 (Cohort B) During the Adjuvant Therapy Phase
Periodo de tiempo: Up to 2.25 years
|
Travel Burden is a composite measure encompassing both objective and subjective components. Objective travel burden is defined by the one-way travel distance (in kilometers [km]) and one-way travel time (in minutes) from the participant's residence to the treatment center. Subjective travel burden will capture the participant's personal experience and will be assessed using patient-reported outcomes collected via dedicated questionnaires. |
Up to 2.25 years
|
|
Cohort B: Change in Intra-participant Travel Burden Between the Neoadjuvant and Adjuvant Treatment Centers
Periodo de tiempo: Up to 2.25 years
|
Travel Burden is a composite measure encompassing both objective and subjective metrices. Objective travel metrics include driving distance and travel time and subjective, patient-reported metrics include out-of-pocket costs, mode of transport, and perceived travel-related challenges. Intra-participant travel burden between the Neoadjuvant and Adjuvant treatment centers will be done as a longitudinal analysis of the change in these metrics from the neoadjuvant to the adjuvant phase. |
Up to 2.25 years
|
|
Difference in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Global Health Status (GHS)/QoL Score, Between Participants of Cohort B and Cohort C
Periodo de tiempo: At 6 months post-baseline
|
EORTC QLQ-C30 is a cancer-specific instrument consisting of 30 questions that evaluates 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea & vomiting, & pain), GHS/QoL & 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). The GHS/QoL questions will be scored on a 7-point scale, with scores ranging from 1=Very poor to 7=Excellent. Scores will be linearly transformed to a range of 0-100. A high score for a GHS/QoL scale indicates a better health-related quality of life (HRQoL). |
At 6 months post-baseline
|
|
Mean Intra-patient Change in the EORTC QLQ-C30 GHS/QoL Score
Periodo de tiempo: Cohorts A, B and C: Baseline to Month 6; Cohort D: Month 6 to Month 12
|
EORTC QLQ-C30 is a cancer-specific instrument consisting of 30 questions that evaluates 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea & vomiting, & pain), GHS/QoL & 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). The GHS/QoL questions will be scored on a 7-point scale, with scores ranging from 1=Very poor to 7=Excellent. Scores will be linearly transformed to a range of 0-100. A high score for a GHS/QoL scale indicates a better HRQoL. |
Cohorts A, B and C: Baseline to Month 6; Cohort D: Month 6 to Month 12
|
|
Time to Neoadjuvant Treatment Initiation
Periodo de tiempo: At Baseline
|
Time to Neoadjuvant Treatment Initiation was defined as time from early breast cancer (eBC) diagnosis to the start of neoadjuvant treatment. Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Time to Surgery
Periodo de tiempo: At Baseline
|
Time to surgery was defined as the time from the neoadjuvant treatment completion to surgery. Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Percentage of Participants Treated at Least Once With Neoadjuvant Therapy
Periodo de tiempo: At Baseline
|
Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Percentage of Participants Not Treated With Neoadjuvant Therapy
Periodo de tiempo: At Baseline
|
Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Percentage of Participants With pCR After Neoadjuvant Systemic Therapy Completion
Periodo de tiempo: At Baseline
|
Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Clinical Trials, Hoffmann-La Roche
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
Otros números de identificación del estudio
- ML46477
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .